ICU Medical (ICUI) officer sells 930 shares at $142.345

ICU Medical (ICUI) disclosed a Form 4 reporting an insider sale by officer Virginia Sanzone, VP and General Counsel.

Accepted by SEC EDGAR 11/12/2025 - 10:55 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ICU Medical (ICUI) disclosed a Form 4 reporting an insider sale by officer Virginia Sanzone, VP and General Counsel. She sold 930 shares of common stock on 11/11/2025 at $142.345 per share, coded “S” for sale. Following the transaction, she beneficially owns 5,456 shares, held directly. The filing notes all shares were sold at the exact price disclosed.

Insights

Insider transactions analyst

Small insider sale; routine Form 4 disclosure, neutral impact.

The report shows a sale of 930 ICUI shares at $142.345 by an officer, coded “S.” After the transaction, direct beneficial ownership stands at 5,456 shares. No derivative activity is listed in the accompanying table.

As a single, modest transaction, this is typically administrative rather than thesis‑changing. Actual market impact depends on broader trading context and future disclosures within periodic filings.

Insider Trade Summary

Net Seller: 930 shares

Net Sell 1 txn

Insider Sanzone Virginia Ruth

Role VP, General Counsel

Sold 930 shs ($132K)

Type	Security	Shares	Price	Value
Sale	Common Stock	930	$142.345	$132K

Holdings After Transaction: Common Stock — 5,456 shares (Direct)

Footnotes (1)

1. F1. All shares sold were sold at the exact price disclosed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ICU Medical (ICUI) disclose in this Form 4?

An officer, Virginia Sanzone (VP, General Counsel), sold 930 shares of common stock on 11/11/2025 at $142.345 per share.

How many ICUI shares does the reporting person hold after the sale?

She beneficially owns 5,456 shares following the reported transaction, held directly.

What was the transaction code on the Form 4 for ICUI?

The transaction was coded “S”, indicating an open-market or private sale of non-derivative securities.

Were any derivative securities reported for ICUI in this filing?

No. The derivative securities table shows no acquisitions or dispositions reported.

Who is the reporting person related to ICU Medical (ICUI)?

The reporting person is Virginia Sanzone, serving as VP, General Counsel at ICU Medical.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanzone Virginia Ruth

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CA 92673

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		S		930	D	$142.345(1)	5,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All shares sold were sold at the exact price disclosed.

	By: Paula Darbyshire, Attorney-in-Fact For: Virginia Sanzone	11/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.